Reaction
Immune-Mediated Endocrinopathy reporting signals
As of the last recalculation, Immune-Mediated Endocrinopathy appears in 140 FAERS reports alongside 3 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 240.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 77 | 240.6 | 240.8 |
| Ipilimumab | 42 | 206.2 | 206.4 |
| Nivolumab | 56 | 142.9 | 143.0 |